BioMedNewsBreaks – Why CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Is ‘One to Watch’

Oct 19, 2020

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. A recent article discussing CNS Pharmaceuticals reads, “The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.”

To view the full article, visit https://ibn.fm/zuyCE

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006.  In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies to be 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

More News

China Rejects Espionage Claims Involving Nvidia C.E.O. Jensen Huang
Nov 9, 2026
China Rejects Espionage Claims Involving Nvidia C.E.O. Jensen Huang

The controversy has intensified scrutiny of Mr. Huang’s ties to Beijing and sparked mixed reactions across Asia, where he is widely popular.

U.S. Commerce Dept. Inquiry Into Megaspeed Was Halted After Nvidia Intervention
Nov 9, 2026
U.S. Commerce Dept. Inquiry Into Megaspeed Was Halted After Nvidia Intervention

An investigation into Megaspeed, a Singapore company that was buying advanced Nvidia A.I. chips, was transferred to the Justice Department after a top Nvidia executive reached out to Commerce Department officials.

Kazakhstan Offers Tajikistan Cooperation, Not a Substitute for Russia
Nov 9, 2026
Kazakhstan Offers Tajikistan Cooperation, Not a Substitute for Russia

Rahmon’s visit to Astana produced 14 agreements, including a fuel supply framework, but Kazakhstan’s deliveries this year show the limits of what it can provide.

Suffield Academy Shaken by I.R.S. Investigation Into Its Leader
Nov 9, 2026
Suffield Academy Shaken by I.R.S. Investigation Into Its Leader

Suffield Academy placed its longtime head of school, Charlie Cahn III, on leave last month after learning that he was the subject of a federal investigation.

Nvidia faces defining test as Jensen Huang probe adds to chip stock turbulence
Nov 9, 2026
Nvidia faces defining test as Jensen Huang probe adds to chip stock turbulence

Nvidia is facing an unprecedented valuation test as a board inquiry into CEO Jensen Huang exposes the US chipmaker to a rare key-person risk, while investors also weigh the midterm elections’ potential impact on Washington’s chip controls and AI regulation. The company’s shares slumped 7.3 per cent as markets opened in the United States on Monday, following Huang’s bombshell confirmation over the weekend that he had been unfaithful to his wife and would cooperate with an investigation into his...

Singapore firm Megaspeed back in the spotlight over Nvidia scandal, China chip allegations
Nov 9, 2026
Singapore firm Megaspeed back in the spotlight over Nvidia scandal, China chip allegations

A little-known Singapore-registered company is embroiled in a mounting love scandal surrounding Nvidia chief Jensen Huang and US allegations of Chinese espionage. Huang’s admission of an extramarital affair has renewed scrutiny of Megaspeed, after media reports identified a former executive of the Singapore firm as the woman involved in the relationship, which US officials suspect was linked to Chinese espionage. Megaspeed, a major Nvidia customer, is believed to have been founded and led by...

India’s Theater Commands: A Never-ending Debate?
Nov 9, 2026
India’s Theater Commands: A Never-ending Debate?

The way forward lies in a phased approach that combines the interests of all three services and that requires a strong political will.

Nvidia fallout: chipmaker faces extensive risks after CEO affair, analysts and lawyers say
Nov 9, 2026
Nvidia fallout: chipmaker faces extensive risks after CEO affair, analysts and lawyers say

As Nvidia launched an investigation into CEO Jensen Huang after he admitted to an extramarital affair, the repercussions threaten not only his three-decade tenure but also the future of the chip giant’s delicate semiconductor trade with China, according to lawyers and analysts. The world’s leading maker of chips for artificial intelligence systems faces an unprecedented corporate and geopolitical storm after its 63-year-old leader told employees that he was unfaithful to his wife and pledged to...

Why Aung San Suu Kyi Is Still the ‘Perfect Hostage’
Nov 9, 2026
Why Aung San Suu Kyi Is Still the ‘Perfect Hostage’

Aung San Suu Kyi’s fate is inextricably linked to the legitimacy of Min Aung Hlaing’s new government.

Beyond LLMs? China forges new path for AI with focus on industrial systems
Nov 9, 2026
Beyond LLMs? China forges new path for AI with focus on industrial systems

China’s artificial intelligence development is expanding beyond general large language models (LLMs) towards a new generation of specialised systems designed to solve real-world industrial problems, according to a leading computer science researcher. Cui Peng, an associate professor at Beijing’s elite Tsinghua University, said that specialist systems capable of analysing industrial data, such as factory sensor readings and financial records, could become a crucial part of AI’s next phase in...

In Malaysia, Najib’s house arrest pits palace against prosecutors
Nov 9, 2026
In Malaysia, Najib’s house arrest pits palace against prosecutors

A growing dispute over former Malaysian prime minister Najib Razak’s house arrest has thrust the attorney general’s powers into the spotlight, raising the spectre of a constitutional clash – though legal experts say it falls short of a full-blown crisis. Najib, 73, was due to move from Kajang Prison to his Kuala Lumpur home on Friday after his political party, Umno, paid a 50 million ringgit (US$12.3 million) fine, fulfilling a condition of a royal pardon issued in September allowing him to...

Indonesia mulls palace bug sweeps after presidential wiretaps
Nov 9, 2026
Indonesia mulls palace bug sweeps after presidential wiretaps

Indonesia will tighten controls on state ⁠surveillance equipment and consider ⁠sweeps of its presidential palace for bugging ⁠devices, a minister said on Monday, following last week’s discovery of illegal wiretaps on the president, top officials and more. The wiretapping scandal led to the arrest of four senior police officers accused of unauthorised monitoring of phones, among them a former national police chief ‌who had recently been appointed President Prabowo Subianto’s chief of staff. The...

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Indo Inquirer

Indo Inquirer is the leading online news network in Indonesia, providing daily breaking news with in-depth news coverage and the best photojournalism. We deliver compelling and diverse engaging stories around the world.

Newsletter